透明细胞型脑膜瘤的辅助立体定向放射外科治疗
本研究评估立体定向放射外科(SRS)对残留或复发透明细胞型脑膜瘤的辅助获益,6例组织学确诊的2级透明细胞型脑膜瘤患者接受SRS,中位随访35.5个月,5/6例经一次或多次SRS后维持肿瘤控制。作者认为SRS应考虑用于手术切除后的早期干预。
要点
- 6例2级透明细胞型脑膜瘤患者接受SRS,中位随访35.5个月,5例维持肿瘤控制。
- 3例首次SRS后即达肿瘤控制,另3例分别在4、22、32个月出现进展。
- 3例进展者中2例经再次SRS获得肿瘤控制。
核心结论
- 6例患者中5例经一次或多次SRS后维持肿瘤控制。
- 作者认为透明细胞型脑膜瘤手术切除后应考虑早期SRS干预。
- 作者建议为最大化肿瘤控制率,确诊透明细胞型脑膜瘤的患者应更积极地治疗并给予更高的边缘剂量。
- 作者建议应告知透明细胞型脑膜瘤患者可能需要多次SRS才能维持肿瘤控制。
研究设计与样本
- 回顾性分析前瞻性维护数据库,纳入6例组织学确诊的2级透明细胞型脑膜瘤患者(3例女性)。
- SRS时中位年龄45岁。
- SRS前5例接受过全切除手术,1例接受过次全切除。
- 中位SRS治疗体积4.7 cc,中位放射外科边缘剂量13 Gy(范围10-15 Gy)。
主要发现
- 中位随访时间35.5个月(范围6-168个月)。
- 3例在首次SRS后达到肿瘤控制。
- 3例分别在首次SRS后4、22、32个月出现肿瘤进展。
- 3例进展者中2例经额外SRS后获得肿瘤控制。
- 1例接受多次SRS的患者出现疑似放射性不良反应,经皮质类固醇治疗后使用贝伐珠单抗成功治疗。
临床怎么用
- 作者认为透明细胞型脑膜瘤手术切除后应考虑早期SRS干预。
- 作者建议为最大化肿瘤控制率,确诊透明细胞型脑膜瘤的患者应更积极地治疗并给予更高的边缘剂量。
- 作者建议应告知透明细胞型脑膜瘤患者可能需要多次SRS才能维持肿瘤控制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Clear cell meningiomas (CCM) are an uncommon meningioma subtype marked by aggressive growth and high rates of recurrence despite initial resection. The present study evaluates the adjuvant benefit of stereotactic radiosurgery (SRS) for residual or recurrent tumors. METHODS: After review of our prospectively maintained database, we identified 6 patients (3 female) with histologically confirmed Grade 2 CCMs. The median age of the patients at the time of SRS was 45 years. Five patients had undergone prior gross total surgical resection and 1 patient had subtotal resection before SRS. The median SRS treatment volume was 4.7 cc and the median radiosurgical margin dose was 13 Gy (range: 10-15 Gy). RESULTS: The median follow-up time was 35.5 months (range 6-168 months). Three patients achieved tumor control after the first SRS procedure. Three patients experienced tumor progression at 4, 22, and 32 months after initial SRS. Tumor control was obtained in 2 of these patients after additional SRS. One patient with multiple SRS procedures had suspected adverse radiation effect that was successfully treated with corticosteroids followed by bevacizumab. CONCLUSIONS: Tumor control was maintained in 5 of 6 patients after one or more SRS procedures. SRS should be considered for early intervention after surgical resection of CCM. To maximize the tumor control rate, patients with diagnosed CCM should be treated more generously and higher margin dose should be prescribed. Patients with CCM should be counselled that more than one SRS may be necessary to provide sustained tumor control.
引用
- Wei Z, Jose SG, Agarwal P, et al. Adjuvant Stereotactic Radiosurgery for Clear Cell Meningiomas. World Neurosurg. 2024. PMID: 38360207. doi:10.1016/j.wneu.2024.02.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。